---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-113203"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2022-04-21T23:59:59+00:00"
generated_at: "2026-06-26T05:45:23.078765+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Homology appoints Albert Seymour President; Tzianabos remains CEO, Seymour gets new equity grant

## Summary
- Albert Seymour promoted to President effective April 21, 2022, while remaining Chief Scientific Officer.
- Arthur Tzianabos resigns as President but continues as Chief Executive Officer of Homology.
- Seymour's base salary increased to $545,000; target annual bonus set at 50% of base salary.
- Seymour receives option to purchase 60,000 shares at $1.78, vesting over 48 months.

## SEC filing metadata
- accession: 0001193125-22-113203
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2022-04-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312522113203/0001193125-22-113203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312522113203/d304763d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-113203
- JSON: https://secwatch.observer/filing/0001193125-22-113203.json
- Plain text: https://secwatch.observer/filing/0001193125-22-113203.txt

## Key facts
- Executive change
  Arthur O. Tzianabos resigned as President at Q32 Bio Inc..
  - Action: resigned
  - Role: President
  source text: Arthur O. Tzianabos, Ph.D., in connection with Dr. Seymour’s promotion, notified the Company on April 19, 2022 of his resignation as President, effective as of April 21, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312522113203/0001193125-22-113203-index.htm
- Executive change
  Albert Seymour was appointed as President at Q32 Bio Inc..
  - Action: appointed
  - Role: President
  source text: On April 19, 2022, the Board of Directors of Homology Medicines, Inc. (the “Company”) appointed Albert Seymour, Ph.D., the Company’s current Chief Scientific Officer, to serve as the Company’s President, effective as of April 21, 2022, in addition to his role as the Company’s Chief Scientific Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312522113203/0001193125-22-113203-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.